US Patent 7183071 Anthrax lethal factor is a MAPK kinase protease
All edits
Edits on 31 Aug, 2023
Golden AI
Edits made to:
Article (+294 characters)
Article
Patent abstract
The present invention relates to in vitro and ex vivo methods of screening for modulators, homologues, and mimetics of lethal factor mitogen activated protein kinase kinase (MAPKK) protease activity, as well as methods of treating cancer by administering LF to transformed cells.
Edits on 23 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 18 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07183071 Anthrax lethal factor is a MAPK kinase protease US Patent 7183071 Anthrax lethal factor is a MAPK kinase protease
Infobox
Patent Number
0718307100
Patent Number
718307100
Edits on 26 Mar, 2023
Golden AI
Infobox
Is a
Patent Jurisdiction
Patent Number
071830710
Date of Patent
February 27, 2007
0Patent Application Number
113269850
Date Filed
January 5, 2006
0Official Website
Patent Primary Examiner
Edits on 23 Sep, 2022
Golden AI
Infobox
Is a
Patent Jurisdiction
Patent Number
071830710
Date of Patent
February 27, 2007
0Patent Application Number
113269850
Date Filed
January 5, 2006
0Official Website
Patent Primary Examiner
Edits on 8 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 20 Nov, 2021
Golden AI
Edits made to:
Infobox (+7 properties)
US Patent 07183071 Anthrax lethal factor is a MAPK kinase protease
Infobox
Is a
Patent jurisdiction
Patent number
07183071
Date of patent
February 27, 2007
Patent application number
11326985
Date Filed
January 5, 2006
Patent primary examiner
Find more entities like US Patent 7183071 Anthrax lethal factor is a MAPK kinase protease
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
